⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for paraproteinemias

Every month we try and update this database with for paraproteinemias cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleNCT05280275
Multiple Myelom...
Neoplasms
Neoplasms, Plas...
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Belantamab Mafo...
Daratumumab
Lenalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaNCT05804032
Multiple Myelom...
Isatuximab
Isatuximab
Lenalidomide
Bortezomib
Dexamethasone
18 Years - 70 YearsUniversity of Heidelberg Medical Center
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaNCT04309084
Multiple Myelom...
Neoplasm, Plasm...
Neoplasms by Hi...
Neoplasms
Hemostatic Diso...
Vascular Diseas...
Cardiovascular ...
Paraproteinemia...
Blood Protein D...
Hematologic Dis...
Hemorrhagic Dis...
Lymphoprolifera...
Immunoprolifera...
Immune System D...
Antineoplastic ...
Analgesics, Non...
Analgesics
Sensory System ...
Peripheral Nerv...
Physiological E...
CYNK-001
18 Years - 75 YearsCelularity Incorporated
Comprehensive Frailty AssessmentNCT02033928
Myeloma, Multip...
Paraproteinemia...
Hematologic Neo...
18 Years - Ohio State University Comprehensive Cancer Center
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.NCT05228470
Elranatamab
Myeloma
Multiple Myelom...
Relapsed Multip...
Refractory Mult...
PF-06863135
BCMA
Bispecific
Bispecific Anti...
BCMA-CD3 Bispec...
MagnetisMM-8
Elranatamab
18 Years - Pfizer
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.NCT05228470
Elranatamab
Myeloma
Multiple Myelom...
Relapsed Multip...
Refractory Mult...
PF-06863135
BCMA
Bispecific
Bispecific Anti...
BCMA-CD3 Bispec...
MagnetisMM-8
Elranatamab
18 Years - Pfizer
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)NCT03162536
Lymphoma, B-Cel...
Small Lymphocyt...
Chronic Lymphoc...
Waldenstrom Mac...
Mantle Cell Lym...
Diffuse Large B...
Richter's Trans...
Follicular Lymp...
Marginal Zone L...
Nemtabrutinib
18 Years - ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.NCT05228470
Elranatamab
Myeloma
Multiple Myelom...
Relapsed Multip...
Refractory Mult...
PF-06863135
BCMA
Bispecific
Bispecific Anti...
BCMA-CD3 Bispec...
MagnetisMM-8
Elranatamab
18 Years - Pfizer
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)NCT03162536
Lymphoma, B-Cel...
Small Lymphocyt...
Chronic Lymphoc...
Waldenstrom Mac...
Mantle Cell Lym...
Diffuse Large B...
Richter's Trans...
Follicular Lymp...
Marginal Zone L...
Nemtabrutinib
18 Years - ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom MacroglobulinemiaNCT02952508
Waldenstrom Mac...
Multiple Myelom...
Chronic Lymphoc...
Small Lymphocyt...
Lymphoplasmacyt...
Marginal Zone L...
Mantle Cell Lym...
Diffuse Large B...
Central Nervous...
Iopofosine I 13...
Iopofosine I 13...
Iopofosine I 13...
18 Years - Cellectar Biosciences, Inc.
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentNCT05147493
Multiple Myelom...
Renal Impairmen...
Neoplasms, Plas...
Neoplasms by Hi...
Neoplasms
Paraproteinemia...
Blood Protein D...
Hematologic Dis...
Isatuximab
Bortezomib
Cyclophosphamid...
Dexamethasone
Lenalidomide
18 Years - Hellenic Society of Hematology
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaNCT01183949
Multiple Myelom...
AT7519M
Bortezomib
18 Years - Astex Pharmaceuticals, Inc.
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaNCT02155634
Multiple Myelom...
Neoplasms
Plasma Cells
Paraproteinemia...
Blood Protein D...
Hematologic Dis...
Therapeutic Use...
Lenalidomide
18 Years - Celgene
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleNCT05280275
Multiple Myelom...
Neoplasms
Neoplasms, Plas...
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Belantamab Mafo...
Daratumumab
Lenalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaNCT01063907
Multiple Myelom...
KW-2478
Bortezomib
18 Years - Kyowa Kirin Co., Ltd.
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNCT05298683
Multiple Myelom...
Renal Impairmen...
Neoplasms, Plas...
Neoplasms by Hi...
Neoplasms
Paraproteinemia...
Blood Protein D...
Hematologic Dis...
Isatuximab
Pomalidomide
Dexamethasone
Acetaminophen (...
Ranitidine (or ...
Diphenhydramine...
18 Years - Hellenic Society of Hematology
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom MacroglobulinemiaNCT02952508
Waldenstrom Mac...
Multiple Myelom...
Chronic Lymphoc...
Small Lymphocyt...
Lymphoplasmacyt...
Marginal Zone L...
Mantle Cell Lym...
Diffuse Large B...
Central Nervous...
Iopofosine I 13...
Iopofosine I 13...
Iopofosine I 13...
18 Years - Cellectar Biosciences, Inc.
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)NCT00773747
Multiple Myelom...
Vorinostat
bortezomib
placebo to vori...
18 Years - Merck Sharp & Dohme LLC
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide RefractoryNCT05581875
Multiple Myelom...
Multiple Myelom...
Neoplasms
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Neoplasms, Plas...
Belantamab Mafo...
Daratumumab
Pomalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's MacroglobulinemiaNCT00113802
Waldenstrom Mac...
Epratuzumab (hL...
18 Years - Gilead Sciences
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM ReadingsNCT01755000
Leukemia
Lymphoma
Paraproteinemia...
Multiple Myelom...
Myelodysplastic...
USCOM scan
Fluid Bolus
18 Years - Washington University School of Medicine
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleNCT05280275
Multiple Myelom...
Neoplasms
Neoplasms, Plas...
Gammopathy, Mon...
Paraproteinemia...
Blood Protein D...
Haematologic Di...
Corneal Disease
Belantamab Mafo...
Daratumumab
Lenalidomide
Dexamethasone
18 Years - Hellenic Society of Hematology
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple MyelomaNCT01183949
Multiple Myelom...
AT7519M
Bortezomib
18 Years - Astex Pharmaceuticals, Inc.
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaNCT00525447
Multiple Myelom...
SGN-40
lenalidomide
dexamethasone
18 Years - Seagen Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: